Premenstrual syndrome and eating misbehavior


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Whatever the cultural and socioeconomic level is, most women perceive psychosomatic and behavioral changes before menstruation. This phenomenon is called premenstrual syndrome (PMS) when the discomfort is so great that it impairs day-to-day activity, relations with the present, and quality of life in a woman. Premenstrual dysphoric disorder is a severe form of PMS. Eating misbehavior that is to some extent responsible for weight fluctuations before menstruation and occasionally takes on the nature of mental disorder is described among the premenstrual symptoms. Eating misbehavior depends on fluctuations in the hormonal profile and on changes in the ratios of steroid hormones. This offers possibilities of using combined estrogen-gestagen contraceptives to treat hormonal imbalance-dependent eating behavioral disorders. The effects of hormonal contraceptives are known to be determined by the pharmacological properties of progestins that enter into their composition. The fourth-generation progestin drospirenone has a unique spectrum of antimineralocorticoid and antiandrogenic activities, which endows drospirenone-containing agents with peculiar therapeutic and preventive effects that are important in eating misbehavior as well.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Irina Kuznetsova

First MSMU of I.M. Sechenov

Email: ms.smith.ivk@gmail.com
Doctor of Medicine, Professor, Chief Researcher of Research Center SRA of female health

Victoria Dil

First MSMU of I.M. Sechenov

Email: dil.nika89@mail.ru
the post-graduate student of department of obstetrics and gynecology of Research Center SRA of female health

Әдебиет тізімі

  1. Villarejo C., Fernández-Aranda F., Jiménez-Murcia S., Peñas-Lledó E., Granero R., Penelo E. et al. Lifetime obesity in patients with eating disorders: increasing prevalence, clinical and personality correlates. Eur. Eat Disord. Rev. 2012; 20(3): 250-4.
  2. Yonkers K.A., O’Brien P.M., Eriksson E. Premenstrual syndrome. Lancet. 2008; 371(9619): 1200-10.
  3. Reed S.C., Levin F.R., Evans S.M. Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of the menstrual cycle in women with and without PMDD (premenstrual dysphoric disorder). Horm. Behav. 2008; 54(1): 185-93.
  4. Di Giulio G., Reissing E.D. Premenstrual dysphoric disorder: prevalence, diagnostic considerations, and controversies. J. Psychosom. Obstet. Gynaecol. 2006; 27(4): 201-10.
  5. Thomas J.J., Vartanian L.R., Brownell K.D. The relationship between eating disorder not otherwise specified (EDNOS) and officially recognized eating disorders: meta-analysis and implications for DSM. Psychol. Bull. 2009; 135(3): 407-33.
  6. Eddy K.T., Dorer D.J., Franko D.L., Tahilani K., Thompson-Brenner H., Herzog D.B. Diagnostic crossover in anorexia nervosa and bulimia nervosa: implications for DSM-V. Am. J. Psychiatry. 2008; 165(2): 245-50.
  7. Miller K.K. Endocrine dysregulation in anorexia nervosa update. J. Clin. Endocrinol. Metab. 2011; 96(10): 2939-49.
  8. Yen J.Y., Chang S.J., Ko C.H., Yen C.F., Chen C.S., Yeh Y.C., Chen C.C. The high-sweet-fat food craving among women with premenstrual dysphoric disorder: emotional response, implicit attitude and rewards sensitivity. Psychoneuroendocrinology. 2010; 35(8): 1203-12.
  9. Keen-Rhinehart E., Ondek K., Schneide J.E. Neuroendocrine regulation of appetitive ingestive behavior. Neuroendocr. Sci. 2013; 7: 13.
  10. Sudo N., Degeneffe D., Vue H., Ghosh K., Reicks M. Relationship between needs driving eating occasions and eating behavior in midlife women. Appetite. 2009; 52(1): 137-46.
  11. Smitka K., Papezova H., Vondra K., Hill M., Hainer V., Nedvidkova J. The role of “mixed” orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with anorexia nervosa and bulimia nervosa. Int. J. Endocrinol. 2013; 2013: 483145.
  12. Jocken J.W.E., Blaak E.E. Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity. Physiol. Behav. 2008; 94: 219-30.
  13. Santollo J., Katzenellenbogen B.S., Katzenellenbogen J.A., Eckel L.A. Activation of ER is necessary for estradiol’s anorexigenic effect in female rats. Horm. Behav. 2010; 58: 872-7.
  14. Butera P.C. Estradiol and the control of food intake. Physiol. Behav. 2010; 99: 175-80.
  15. Hirschberg A.L. Sex hormones, appetite and eating behaviour in women. Maturitas. 2012; 71(3): 248-56.
  16. Nohara K., Zhang Y., Waraich R.S., Laque A., Tiano J.P., Tong J. et al. Early-life exposure to testosterone programs the hypothalamic melanocortin system. Endocrinology. 2011; 152(4): 1661-9.
  17. Clegg D.J., Brown L.M., Zigman J.M., Kemp C.J., Strader A.D., Benoit S.C. et al. Estradiol-dependent decrease in the orexigenic potency of ghrelin in female rats. Diabetes. 2007; 56(4): 1051-8.
  18. Monteleone P., Fabrazzo M., Tortorella A., Martiadis V., Serritella C., Maj M. Circulating ghrelin is decreased in non-obese and obese women with binge eating disorder as well as in obese non-binge eating women, but not in patients with bulimia nervosa. Psychoneuroendocrinology. 2005; 30(3): 243-50.
  19. Hirschberg A.L., Naessén S., Stridsberg M., Byström B., Holtet J. Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. Gynecol. Endocrinol. 2004; 19(2): 79-87.
  20. Sundblad C., Landén M., Eriksson T., Bergman L., Eriksson E. Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study. J. Clin. Psychopharmacol. 2005; 25(1): 85-8.
  21. Reynolds C.J., Buckley J.D., Weinstein P., Boland J. Are the dietary guidelines for meat, fat, fruit and vegetable consumption appropriate for environmental sustainability? A review of the literature. Nutrients. 2014; 6(6): 2251-65.
  22. Wadden T., Butryn M., Byrne K. Efficacy of lifestyle modification for long-term weight control. Obes. Res. 2004; 12(Suppl.): 151S-62S.
  23. Berga S.L., Loucks T.L. Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann. N. Y. Acad. Sci. 2006; 1092: 114-29.
  24. Товсултанова М.С. Некоторые аспекты комплексной терапии социально-стрессовых расстройств. В кн.: Сборник тезисов III научно-практической конференции с международным участием «Вегетативные расстройства в клинике нервных и внутренних болезней». М.; 2010: 61. [Tovsultanova M.S. Some aspects of complex therapy of social and stressful diseases. In.: Book of abstracts of the III scientific and practical conference with the international participation “Vegetative disturbances in clinic of nervous and internal diseases”. M., 2010: 61. In Russ.]
  25. Вейн А.М., Вознесенская Т.Г. Депрессия в неврологической практике. М.: МИА; 2007. 265 с. [Vane A.M., Voznesenskaya T.G. Depression in neurological practice. M.: MIA; 2007. 265 p. In Russ.]
  26. Yonkers K.A., Brown C., Pearlstein T.B., Foegh M., Sampson-Landers C., Rapkin A. Efficacy of a new low-dose oral contraceptive with drospire none in premenstrual dysphoric disorder. Obstet. Gynecol. 2005; 106(3): 492-501.
  27. Pearlstein T.B., Bachmann G.A., Zacur H.A., Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005; 72(6): 414-21.
  28. Naessén S., Carlström K., Byström B., Pierre Y., Hirschberg A.L. Effects of an antiandrogenic oral contraceptive on appetite and eating behavior in bulimic women. Psychoneuroendocrinology. 2007; 32(5): 548-54.
  29. Bertolini S., Elicio N., Cordera R., Gapitanio G.L., Montagna G., Croce S. et al. Effects of three low-dose oral contraceptive formulations on lipid metabolism. Acta Obstet. Gynecol. Scand. 2007; 66(4): 327-32.
  30. Gallo M.F., Lopez L.M., Grimes D.A., Schulz K.F., Helmerhorst F.M. Combination contraceptives: effects on weight. Cochrane Database Syst. Rev. 2008; (4): CD003987.
  31. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of unique progestogen. Contraception. 2006; 41: 875-86.
  32. Басова О.Н., Волков В.Г. Опыт применения комбинированного орального контрацептива, содержащего дроспиренон. В кн.: Материалы Х юбилейного Всероссийского научного форума «Мать и дитя». М.; 2009: 259-60. [Basova O.N., Volkov V.G. Experience of use of the combined oral contraceptive containing drospirenone. In: Materials of the 10th anniversary All-Russian scientific forum “Mother and Child”; 2009: 259-260. In Russ.]

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2014

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>